Cytotoxicity of Zardaverine in Embryonal Rhabdomyosarcoma from a Costello Syndrome Patient

Donna M Cartledge; Katherine M Robbins; Katherine M Drake; Rachel Sternberg; Deborah L Stabley; Karen W Gripp; E Anders Kolb; Katia Sol-Church; Andrew D Napper

doi:10.3389/fonc.2017.00042

Cytotoxicity of Zardaverine in Embryonal Rhabdomyosarcoma from a Costello Syndrome Patient

Front Oncol. 2017 Apr 3:7:42. doi: 10.3389/fonc.2017.00042. eCollection 2017.

Authors

Donna M Cartledge¹, Katherine M Robbins^{2

3}, Katherine M Drake¹, Rachel Sternberg¹, Deborah L Stabley², Karen W Gripp⁴, E Anders Kolb⁵, Katia Sol-Church², Andrew D Napper¹

Affiliations

¹ High-Throughput Screening and Drug Discovery Laboratory, Nemours Center for Childhood Cancer Research, Nemours Biomedical Research, Nemours/A.I. duPont Hospital for Children, Wilmington, DE, USA.
² Nemours Biomolecular Core Laboratory, Nemours Biomedical Research, Nemours/A.I. duPont Hospital for Children, Wilmington, DE, USA.
³ Biological Sciences, University of Delaware, Newark, DE, USA.
⁴ Division of Genetics, Nemours/A.I. duPont Hospital for Children, Wilmington, DE, USA.
⁵ Nemours Center for Cancer and Blood Disorders, Nemours/A.I. duPont Hospital for Children, Wilmington, DE, USA.

Abstract

Costello syndrome (CS) patients suffer from a very high 10% incidence of embryonal rhabdomyosarcoma (ERMS). As tools to discover targeted therapeutic leads, we used a CS patient-derived ERMS cell line (CS242 ERMS) harboring a homozygous p.G12A mutation in HRAS, and a control cell line derived from the same patient comprising non-malignant CS242 fibroblasts with a heterozygous p.G12A HRAS mutation. A library of 2,000 compounds with known pharmacological activities was screened for their effect on CS242 ERMS cell viability. Follow-up testing in a panel of cell lines revealed that various compounds originally developed for other indications were remarkably selective; notably, the phosphodiesterase (PDE) inhibitor zardaverine was at least 1,000-fold more potent in CS242 ERMS than in the patient-matched non-malignant CS242 fibroblasts, other ERMS, or normal fibroblasts. Chronic treatment with zardaverine led to the emergence of resistant cells, consistent with CS242 ERMS comprising a mixed population of cells. Many PDE inhibitors in addition to zardaverine were tested on CS242 ERMS, but almost all had no effect. Interestingly, zardaverine and analogs showed a similar cytotoxicity profile in CS242 ERMS and cervical carcinoma-derived HeLa cells, suggesting a mechanism of action common to both cell types that does not require the presence of an HRAS mutation (HeLa contains wild type HRAS). Two recent studies presented possible mechanistic explanations for the cytotoxicity of zardaverine in HeLa cells. One revealed that zardaverine inhibited a HeLa cell-based screen measuring glucocorticoid receptor (GR) activation; however, using engineered HeLa cells, we ruled out a specific effect of zardaverine on signaling through the GR. The second attributed zardaverine toxicity in HeLa cells to promotion of the interaction of phosphodiesterase 3A and the growth regulatory protein Schlafen 12. We speculate that this work may provide a possible mechanism for zardaverine action in CS242 ERMS, although we have not yet tested this hypothesis. In conclusion, we have identified zardaverine as a potent cytotoxic agent in a CS-derived ERMS cell line and in HeLa. Although we have ruled out some possibilities, the mechanism of action of zardaverine in CS242 ERMS remains to be determined.

Keywords: Costello syndrome; cell viability; cytotoxicity; high-throughput screening; inhibitor; phosphodiesterase; sarcoma.

Abstract

Grants and funding